SFI
TNGX icon

Susquehanna Fundamental Investments’s Tango Therapeutics TNGX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-157,233
Closed -$1.32M – 686
2025
Q3 		$1.32M Sell
157,233
-2,604
-2% -$17.6K 0.05% 292
2025
Q2 		$818K Sell
159,837
-72,929
-31% -$180K 0.02% 481
2025
Q1 		$319K Sell
232,766
-114,505
-33% -$281K ﹤0.01% 943
2024
Q4 		$1.07M Buy
+347,271
New +$1.61M 0.02% 686
2024
Q2 		$536K Buy
62,417
+28,155
+82% +$218K 0.01% 680
2024
Q1 		$272K Buy
+34,262
New +$367K 0.01% 571

Other funds holding TNGX

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna Fundamental Investments's TNGX Position: Q4 2025 in Review

Susquehanna Fundamental Investments sold out of Tango Therapeutics (TNGX) in Q4 2025, closing a stake of 157,233 shares — an estimated $1.32M sold.

Susquehanna Fundamental Investments first reported a position in TNGX in Q1 2024 and held it in 6 quarters. The position peaked at $1.32M in Q3 2025. 170 funds tracked by Wall St. Rank hold TNGX as of Q4 2025.

  • Susquehanna Fundamental Investments reported no remaining Tango Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 157,233 Tango Therapeutics shares in Q4 2025, an estimated $1.32M.
  • Susquehanna Fundamental Investments first reported a position in Tango Therapeutics in Q1 2024 and held it in 6 quarters.
  • Susquehanna Fundamental Investments's Tango Therapeutics position peaked at $1.32M in Q3 2025.
  • 170 funds tracked by Wall St. Rank held Tango Therapeutics as of Q4 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2025, filed 17 Feb 2026.